Kodiak Sciences Inc - Company Profile

Powered by

All the data and insights you need on Kodiak Sciences Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Kodiak Sciences Inc Strategy Report

  • Understand Kodiak Sciences Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Kodiak Sciences Inc: Overview

Select Item

Kodiak Sciences Inc (Kodiak Sciences) is a biopharmaceutical company that develops and transformative therapeutics to treat retinal diseases. Its pipeline products includes tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer, which treats wet age-related macular degeneration (AMD); KSI-501, a bispecific conjugate for pro-inflammatory cytokine interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) and KSI-101, unconjugated bispecific protein that targets interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) developed for retinal inflammatory conditions. Kodiak Sciences is headquartered in Palo Alto, California, the US.

 Gain a 360-degree view of Kodiak Sciences Inc and make more informed decisions for your business Gain a 360-degree view of Kodiak Sciences Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 1200 Page Mill Rd, Palo Alto, California, 94304
Website kodiak.com
Telephone 1 650 2810850
No of Employees 111
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange KOD (NASD)
EPS XYZ
Net Income (2022) XYZ 22% (2022 vs 2021)
Market Cap* $179.6M
   
   
* As of and is in US$
View Kodiak Sciences Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Kodiak Sciences Inc premium industry data and analytics

50+

Catalyst Calendar

Proactively evaluate Kodiak Sciences Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Kodiak Sciences Inc’s relevant decision makers and contact details.

10+

Clinical Trials

Determine Kodiak Sciences Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

7

Pipeline Drugs

Identify which of Kodiak Sciences Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products
Pipeline
KSI-301: Retinal Vein Occlusion, Wet Age-Related Macular Degeneration and Diabetic Retinopathy
KSI-101: Macular Edema
XYZ
XYZ
XYZ
Understand Kodiak Sciences Inc portfolio and identify potential areas for collaboration Understand Kodiak Sciences Inc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Kodiak Sciences Inc Axsome Therapeutics Inc Flexion Therapeutics Inc Ocular Therapeutix Inc Apoplogic Pharmaceuticals Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Palo Alto New York Burlington Bedford Aurora
State/Province California New York Massachusetts Massachusetts Colorado
No. of Employees 111 545 257 267 -
Entity Type Public Public Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Victor Perlroth, MD Chairman; Chief Executive Officer Executive Board 2009 50
John Borgeson Chief Financial Officer; Executive Vice President Senior Management 2016 61
Almas Qudrat Senior Vice President - Quality Operations Senior Management 2018 -
Pablo Velazquez-Martin, M.D. Senior Vice President - Clinical Research and Development Senior Management 2018 -
Laurent Ducry Vice President - Biologics Development and Manufacturing Senior Management - -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Kodiak Sciences Inc key executives to enhance your sales strategy Gain insight into Kodiak Sciences Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward